NeoGenomics price target lowered to $21 from $23 at BTIG

BTIG lowered the firm’s price target on NeoGenomics to $21 from $23 and keeps a Buy rating on the shares. The company reported a “solid” Q1 earnings beat, but the post-earnings decline is an “over-reaction” to the management’s commentary that they’re evaluating M&A, which the market interpreted to require dilutive financing, the analyst tells investors in a research note.